Please login to the form below

Not currently logged in
Email:
Password:

Pixuvri

This page shows the latest Pixuvri news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails

CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure. ... The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a

Latest news

  • CTI launches cancer drug Pixuvri in UK CTI launches cancer drug Pixuvri in UK

    Now available to treat form of non-Hodgkin lymphoma. Cell Therapeutics Inc (CTI) has launched its cancer treatment Pixuvri in the UK. ... were later resolved at the end of 2013, meaning Pixuvri is available for reimbursement.

  • NICE relents and gives Pixuvri limited backing NICE relents and gives Pixuvri limited backing

    Recommends Cell Therapeutics drug for an aggressive form of cancer. Cell Therapeutics has scraped a limited recommendation from NICE for its non-Hodgkin's lymphoma drug Pixuvri. ... Cell Therapeutics' first drug on the market, Pixuvri was recommended by

  • NICE unmoved by Pixuvri access scheme NICE unmoved by Pixuvri access scheme

    Cell Therapeutics now has another consultation period in which it can try and convince NICE to recommend Pixuvri. ... The NICE guidance is the latest hurdle for Cell Therapeutics in a series of challenges related to Pixuvri – the company's first drug

  • Roche wins conditional EU approval for cancer drug Erivedge Roche wins conditional EU approval for cancer drug Erivedge

    Cell Therapeutics' Pixuvri (pixantrone) for non-Hodgkin B-cell lymphoma.

  • Cell Therapeutics fails to gain NICE backing for blood cancer drug Cell Therapeutics fails to gain NICE backing for blood cancer drug

    Watchdog says not enough evidence to show Pixuvri is more effective than current treatments. ... demonstrates Pixuvri is a cost-effective therapy for this end-of-life disease population,” said Dr James Bianco, president and CEO of Cell Therapeutics.

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... This exclusion of trial data from other

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics